Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

by Breder, V., Cheng, A.-L, Ducreux, M., Finn, R.S, Galle, P.R, Ikeda, M., Kaseb, A.O, Kim, T.-Y, Kudo, M., Li, D., Li, L., Lim, H.Y, Ma, N., Merle, P., Nicholas, A., Qin, S., Verret, W., Wang, Y., Zhu, A.X
Published 2022